Overview of Artesol

Quick Facts

Property	Description
Active Ingredient	Cilostazol
Form	Tablet
Pharmacological Class	Selective Phosphodiesterase 3 (PDE3) Inhibitor
General Purpose	Optimizing peripheral blood flow
Origin	Synthetic, 2-oxyquinolone derivative

What is Artesol and What is its Composition? (Identity and Composition Block)

Artesol is a prescription-only pharmaceutical preparation whose sole active ingredient is Cilostazol. Chemically, Cilostazol is a synthetic small molecule recognized as a 2-oxyquinolone derivative. The medicine is supplied as a single-ingredient product in the dosage form of tablets, which are specifically intended for oral administration.

The composition is limited to the active substance, Cilostazol, combined with the necessary solid excipients for tablet formulation. This adherence to a single active ingredient and its standardized oral form ensures a consistent, measurable delivery of the selective PDE3 inhibitor.

Artesol's Pharmacological Class and Dual Action (Classification and Purpose Block)

Artesol is categorized fundamentally as a selective phosphodiesterase 3 (PDE3) inhibitor, placing it within the broader group of miscellaneous cardiovascular agents. Cilostazol's core action is crucial for managing symptoms related to circulatory impairment.

This classification directly relates to the drug's mechanism: it selectively inhibits phosphodiesterase activity, thereby elevating levels of cyclic adenosine monophosphate (cAMP). This core biochemical effect results in a crucial dual action, making Artesol both a powerful vasodilator and an effective antiplatelet agent. Its general purpose is clinically recognized for its ability to optimize peripheral circulation by promoting the widening of blood vessels and reducing the tendency of platelets to aggregate.

Regulatory References

U.S. National Library of Medicine

What side effects are possible with Artesol?

Possible side effects and safety information

The officially documented safety profile for Artesol (Cilostazol) organizes possible effects by frequency and physiological system, emphasizing both common effects and critical safety limitations.

Adverse Reactions by Classification

The most frequently occurring effects, classified as very common in regulatory documents (affecting 1 in 10 individuals or more), primarily involve the nervous and digestive systems. These commonly reported reactions include headache, diarrhea, and abnormal stools. Other frequently observed effects, classified as common (affecting up to 1 in 10 individuals), include palpitation, tachycardia (increased heart rate), dizziness, nausea, and peripheral edema.

Rare and postmarketing reports documented in official labeling address serious health concerns, including Intracranial hemorrhage, severe hematologic abnormalities (such as Aplastic Anemia), and critical cardiac events (such as Heart failure and Myocardial infarction).

Critical Safety Restrictions and High-Risk Populations

Official regulatory information mandates strict limitations on the use of Artesol based on pre-existing health conditions, reflecting the drug's antiplatelet and PDE3 inhibitor activity:

Congestive Heart Failure: The medicine is explicitly contraindicated in patients with Congestive Heart Failure (CHF) of any severity, which is highlighted as a critical safety concern.
Bleeding Risk: Use is contraindicated in individuals with any known predisposition to bleeding, such as active stomach ulceration or a recent hemorrhagic stroke.
Impaired Organ Function: It is contraindicated in patients with severe renal impairment or with moderate or severe hepatic impairment.

Adverse effects are often concentrated within the first month of treatment. Furthermore, the regulatory safety framework requires specific monitoring and a dose reduction when the medicine is co-administered with certain strong inhibitors of drug-metabolizing enzymes, due to increased exposure and higher risk of adverse reactions.

Overdose and Emergency Response

Artesol Overdose and When to Seek Help

Official regulatory information describes an Artesol (Cilostazol) overdose as presenting with exaggerated pharmacological effects, primarily on the cardiovascular system. Documented signs include severe headache, diarrhea, dizziness, fainting, and changes to circulation such as hypotension (low blood pressure) and tachycardia (fast or irregular heartbeat).

Documented Severity and Emergency Action

Classification Detail	Regulatory Statement
Serious Outcomes	Potential for cardiac arrhythmias (irregular heart rhythm).
Antidote Information	No specific antidote is known for this overdose.

All suspected or known overdoses require immediate medical attention. Regulators mandate calling emergency services (e.g., 911) if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Furthermore, the official guidance requires that the individual contact a poison control center.

Management procedures, which are strictly supportive, include medically appropriate interventions such as emptying the stomach via induced vomiting or gastric lavage, followed by symptomatic and supportive treatment under hospital monitoring to manage the risk of cardiac complications.

Therapeutic Uses of Artesol

What Artesol Treats: Main Uses and Benefits

Artesol (Cilostazol) is commonly used to help with the symptomatic management of Peripheral Arterial Disease (PAD). Its therapeutic focus is generally on assisting with the improvement of functional capacity in patients whose daily lives are limited by symptoms related to physical discomfort caused by reduced circulation in their lower limbs. This includes helping to ease symptoms related to physical discomfort caused by reduced circulation.

Artesol is commonly applied in addressing the symptom clusters of intermittent claudication, a condition where patients experience aching, cramping, or heaviness in the leg muscles during walking. The primary use is to address groups of symptoms that may become intense or disruptive, such as leg cramping and pain during exercise.

Easing Symptoms and Supporting Stability

The medication is applied in addressing symptom clusters that interfere with daily comfort. In situations where patients experience pain associated with claudication, the medication may assist with maintaining functional stability, which supports patients in potentially increasing the distance they can walk. This ultimately contributes to improved day-to-day comfort and helps maintain a sense of stability when symptoms are more noticeable.

“The application is relevant in conditions characterized by periods of heightened symptoms and is generally used as a supportive measure to help patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Claudication

Property	Description
Primary Indication	Symptomatic relief of Intermittent Claudication.
Key Symptom Domain	Exercise-induced cramping, aching, and heaviness in leg muscles.
Functional Benefit	Supports maintenance of functional stability and supports efforts to increase walking distance.
Usage Context	Applied in chronic conditions involving episodic or fluctuating manifestations.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility for Artesol (Cilostazol)

Artesol is officially approved for use in adults with Intermittent Claudication who have mild or no hepatic or renal impairment. Older adults may use the medicine without demonstrated geriatric-specific limitations. Use in children and adolescents is officially not established due to a lack of safety and efficacy data.

Absolute Non-Eligibility (Contraindications)

Use of Artesol is strictly prohibited in several patient groups. This includes individuals with heart failure of any severity and those with a history of severe cardiac events, such as myocardial infarction or coronary intervention within the last six months, or severe tachyarrhythmias. It is also contraindicated in cases of severe renal impairment ( CrCl le 25 mL/min) or moderate or severe hepatic impairment.

High Bleeding Risk and Pregnancy

Patients with any known predisposition to bleeding, including active peptic ulceration or recent hemorrhagic stroke, must not use Artesol. The medicine is also contraindicated for patients taking two or more additional antiplatelet or anticoagulant agents. Artesol is contraindicated during pregnancy and not recommended for use while breastfeeding.

What should I know about interactions with other medicines?

Artesol (Cilostazol) has officially documented interaction patterns that are classified by regulatory authorities into pharmacokinetic and pharmacodynamic domains. Co-administration is formally contraindicated with other selective Phosphodiesterase 3 (PDE3) inhibitors and in patients diagnosed with congestive heart failure of any severity. Use is also prohibited in the presence of hemostatic disorders or active pathologic bleeding.

Significant pharmacokinetic interactions occur with medicines classified as inhibitors of the CYP3A4 and CYP2C19 enzymes, which are responsible for Artesol's clearance. Strong CYP3A4 inhibitors, such as ketoconazole, can increase the plasma concentration of Artesol by over 100%. Other interacting agents, including erythromycin, diltiazem, and omeprazole, are documented to increase the exposure of Artesol or its active metabolites.

Pharmacodynamic interactions with other antiplatelet agents (e.g., aspirin) or anticoagulants may result in an additive effect, increasing the potential for bleeding, according to official labeling. Furthermore, a high-fat meal or grapefruit juice can increase the drug's absorption and resulting exposure. This food–drug interaction establishes an administration-timing rule: Artesol must be taken on an empty stomach, separated from food by at least 30 minutes before or 2 hours after a meal. Caution is also noted in official labeling regarding patients with severe renal or hepatic impairment due to altered metabolite exposure.

Mechanism of Action

How Artesol Works

Artesol (Cilostazol) exerts its function through the selective inhibition of the Phosphodiesterase 3 (PDE3) enzyme. This enzyme normally catalyzes the rapid breakdown of the intracellular second messenger, cyclic adenosine monophosphate (cAMP). By interfering with PDE3 activity, the mechanism increases and stabilizes cAMP concentrations within targeted cells, generating a cascade that leads to biological effects on blood vessels and blood components.

This elevation of cAMP triggers parallel mechanistic cascades in the vascular smooth muscle cells and in platelets. In the smooth muscle, increased cAMP activates Protein Kinase A, causing arterial relaxation (vasodilation). Concurrently, in platelets, the same increase suppresses the signaling pathways required for aggregation. These combined effects on vessel tone and blood components constitute the drug's primary physiological function.

The mechanism is not strictly localized; since the PDE3 enzyme is also expressed in the myocardium (heart muscle), its inhibition leads to predictable positive chronotropy and inotropy as an inherent systemic consequence. The overall pharmacological effect is a cumulative result of the parent drug and its active metabolites, which share the same PDE3 inhibitory mechanism.

Dosage and Administration Information

Artesol (Cilostazol) is administered exclusively via the oral route as a tablet, available in 50 mg and 100 mg strengths. The standardized adult regimen for its approved use is 100 mg taken twice daily, establishing the mandatory frequency pattern. No specific dose adjustment is required for older adults, mild hepatic impairment, or minor renal impairment (creatinine clearance greater than 25 mL/min).

A critical principle of its use is the time-of-dose relationship to food. The medicine must be taken in a fasting state to manage absorption; specifically, it should be administered 30 minutes before or 2 hours after both breakfast and dinner. Taking the dose with food increases plasma concentrations and is discouraged.

The treatment protocol is structured to include a mandatory observation period. Established prescribing guidelines state that patients may require up to 12 weeks of continuous use for assessment. If symptomatic improvement is not observed after this period of three months, the treatment should be discontinued. Furthermore, the dosage must be adjusted when used concurrently with certain other medications: a reduced dose of 50 mg twice daily is required when co-administered with strong or moderate inhibitors of the CYP3A4 or CYP2C19 enzymes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Action and Proposed Effects

The research summarized focused on evaluating the effects of the drug. Studies reviewed included research focusing on biochemical indicators in the central nervous system.

Research has explored whether the drug is associated with changes in symptom severity scores (measured by the ABC Scale). The research findings suggested an association with a change in the score at the 12-week endpoint as observed in multiple randomized controlled trials (RCTs). The timeline of observed changes varied across the research reviewed.

Secondary Findings and Safety Profile

Studies have also examined whether the drug influences sleep quality in participants with the condition. The results were mixed, with some studies reporting no significant difference compared to placebo, while other, smaller studies reported an observed effect on self-reported sleep metrics. It is not yet clear whether the drug consistently impacts sleep quality.

Information is available regarding the adverse event profile reported in the clinical trials. The study reports noted the presence of specific adverse events, which were primarily mild. The studies reviewed included patients with various health profiles.

Combination Therapy Studies

Research evaluated the use of this combination therapy (Drug + Standard Treatment). Studies examined whether this combination treatment led to a greater change in primary outcome measure than the standard treatment alone. The findings suggested an association with a difference in the primary outcome measure between the two groups, but evidence remains limited regarding its long-term impact compared to standard treatment.

Studies have explored the effects of Drug A administered alongside Drug B. The research findings suggested an association with an increase in metabolite Y concentration in participants. Further research is required to understand the clinical significance of this change.

Frequently Asked Questions (FAQ)

Common questions about Artesol (FAQ)

Q: What happens if I miss a day of Artesol?

A: Official drug information provides guidance for a missed dose. Official documents describe that if a dose is missed, it can be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is typically skipped to maintain the regular schedule. Taking a double dose to compensate for the missed one is not recommended.

Q: How long do I need to take Artesol before I see any change?

A: Regulatory documents indicate that continuous use for up to 12 weeks may be required before a prescriber can properly assess whether symptomatic improvement has occurred. The official information states that this 12-week period is essential for assessment.

Q: What happens if I stop taking Artesol suddenly?

A: Official prescribing information emphasizes that if there is a feeling that the medicine is not working, consultation with the prescriber is recommended before discontinuing use. This instruction is highlighted because the medicine should not be stopped without first consulting with the prescribing professional.

Q: What is the recommended duration of Artesol treatment?

A: Official instructions structure the treatment around a mandatory assessment period of up to 12 weeks of continuous use. If improvement is not observed after this period, official guidance requires the treatment to be discontinued. If improvement is observed, the duration of continued use is determined based on the assessment of the prescriber.

Q: Can I take Artesol with my vitamins or supplements?

A: Official drug information suggests that patients should inform their prescriber about all other products being used, including vitamins, nutritional supplements, and herbal products. Official labeling suggests informing the prescriber about all products being used, as they may require consideration for monitoring.

Q: Is Artesol the same as other medicines for the same condition?

A: Artesol has a specific classification, belonging to the pharmacological class of selective Phosphodiesterase 3 (PDE3) inhibitors. This classification defines its dual effects as both a vasodilator (widens blood vessels) and an antiplatelet agent (reduces blood clotting tendency). Official information defines it by this unique mechanism and action.

Q: Can Artesol cause weight gain?

A: Official safety information indicates that patients should consult a physician immediately if they experience sudden weight gain, as this may be a signal for a serious cardiac event. Weight gain is not listed as a common, isolated side effect in official documents.

Q: Does Artesol affect my sleep?

A: Research has examined whether the medicine influences sleep quality in participants. Studies reported mixed results, with some finding no significant difference compared to placebo, while other, smaller studies reported an observed effect on self-reported sleep metrics. A consistent conclusion on sleep impact is not yet established based on the evidence reviewed.

Q: Can men and women use Artesol the same way?

A: Official regulatory labeling applies the same use conditions and dosage regimen to all adults. No sex-specific dose adjustments or contraindications are noted in the official prescribing information for adult men and women.

Q: Is Artesol a type of antibiotic?

A: No, Artesol is not an antibiotic. It is officially categorized as a selective Phosphodiesterase 3 (PDE3) inhibitor, placing it within the pharmacological class of miscellaneous cardiovascular agents.

Q: Does taking Artesol mean I can stop following other lifestyle changes?

A: Regulatory information defines Artesol as a second-line treatment. This means it is intended for patients whose symptoms were not sufficiently improved by initial non-drug treatments, such as supervised exercise programs and stopping smoking, which should typically be maintained as part of the overall management plan.

Q: How is Artesol different from the medicine my friend is taking for a similar issue?

A: Artesol is a selective Phosphodiesterase 3 (PDE3) inhibitor, defined by its specific chemical structure and dual action as both a vasodilator and an antiplatelet agent. This pharmacological classification and mechanism of action distinguish it from other medicines that may be used for similar symptoms.

Q: Is it normal to feel tired when first starting Artesol?

A: While a general feeling of tiredness or weakness has been documented in rare post-marketing reports, official regulatory labeling does not classify it as a common or very common side effect reported in clinical trials. Any new or unexpected symptoms can be discussed with the prescriber.

Q: Are there any long-term side effects noted in studies about Artesol?

A: Official safety documents include rare post-marketing reports that address severe long-term health concerns. These include specific hematological abnormalities and critical cardiac events. The overall safety profile is a cumulative record of clinical trial data and these post-marketing observations.

Q: What kind of studies led to Artesol's approval?

A: The research base that supported the approval of Artesol includes findings from multiple Randomized Controlled Trials (RCTs). These studies evaluated the drug's effects and safety profile against a placebo over specific time periods in a controlled manner.

Q: What should I do if I think Artesol is not helping?

A: Official prescribing information states that treatment should be assessed for improvement after 12 weeks of continuous use. If you have concerns that the medicine is not working, official information describes that consultation with the prescriber is recommended for further guidance and assessment.

Q: Can Artesol be used by teenagers?

A: Official regulatory information indicates that use in children and adolescents (including teenagers) is officially not established because safety and efficacy data have not been collected for these groups.

Q: How does Artesol compare to non-drug treatments for this condition?

A: Regulatory guidelines indicate that Artesol is intended as a second-line option in the treatment pathway. This means it is used for patients who have not experienced sufficient improvement from non-drug treatments, such as exercise programs and other lifestyle changes.

Q: Has Artesol been studied in people from diverse backgrounds?

A: The research overview states that the studies reviewed included patients with various health profiles. This level of patient diversity is a factor considered in the drug's clinical development and regulatory review process.

Q: What kind of monitoring is typically involved when taking Artesol?

A: Monitoring requirements are determined based on individual assessment. The safety profile suggests that observation for signs of bleeding may be necessary, especially when the medicine is co-administered with other antiplatelet or anticoagulant agents. Assessment of heart function may also be considered.

How should Artesol be stored and disposed of?

Storage Requirements

Artesol (Cilostazol) tablets must be stored at Controlled Room Temperature (CRT), maintaining a temperature range of 20°C to 25°C (68°F to 77°F). It is required that the product be kept in the container it came in, which must remain tightly closed, and stored away from excess heat and moisture.

To ensure safety, the medicine must be stored out of the sight and reach of children at all times. Do not use the tablets after the expiry date printed on the packaging.

Disposal Instructions

Official regulations require that unused or expired Artesol must not be thrown away with household waste or disposed of via wastewater, which helps protect the environment. For proper disposal, consult a pharmacist for guidance on disposing of medicines that are no longer needed.

Artesol